You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959
SBC: T3D Therapeutics, Inc. Topic: NIAT3D-959 is a new chemical entity, orally delivered, small molecule, dual nuclear receptor agonist aimed at improving dysfunctional brain glucose energy and lipid metabolism in Alzheimer’s disease (AD), it is non- amyloid/non-tau-directed. Metabolic homeostasis, inherently altered in AD, leads to protein misfolding resulting in plaque formation, tangle formation and inflammation. Exploratory huma ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A next generation cross-serotype binding antitoxin for treatment of post-exposure botulinum poisoning
SBC: NIGHTHAWK BIOSCIENCES, INC. Topic: NIAIDPROJECT SUMMARY Botulinum poisoning is a rare neurotoxin-mediated syndrome that results in progressive respiratory and muscular paralysis and leads to death if untreated. Aerosolized botulinum neurotoxins (BoNT) are particularly lethal and of major concern as potential biological weapons. Given this concern, the U.S. has stockpiled the only approved antidote for BoNT poisoning, BAT®, to be used i ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform
SBC: ISABL INC. Topic: NCIProject Summary Isabl Inc. is a Memorial Sloan Kettering Cancer Center spin out, aiming to launch a cancer whole genome and transcriptome sequencing (cWGTS) diagnostic test for pediatric and rare cancer patients. The product of this SBIR is Isabl GxT, a precision medicine platform that incorporates cWGTS data into a robust data science framework to enable clinically actionable reporting in a clini ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Innovative Sorbents for Stabilizing Per- and Polyfluoroalky Substances (PFAS) in Soil Contaminated by Aqueous Film-forming Foam (AFFF)
SBC: Regenerative Solutions, Inc. Topic: NIEHSProject Summary/Abstract: Per- and polyfluoroalkyl substances (PFAS) are a group of chemicals consisting of thousands of synthetic organic compounds in which the hydrogen atoms bound to the carbon backbones are fully or partially substituted with fluorine. Due to their widespread use, PFAS are detected ubiquitously. Owing to the nature of PFAS being persistent, bioaccumulative, and toxic, cleaning ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
SBC: Halomine Inc. Topic: 400Abstract: Catheter-associated urinary tract infection (CAUTI) is the most common type of healthcare-associated infection, however currently there is no effective technology to address the problem. Antimicrobial (anti-biofilm) functionality on the catheter surface is an important field that has gained a lot of attention; however, commercial applications are limited due to a lack of infection contro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A single dose anti-scarring therapeutic for the cornea
SBC: DUB BIOLOGICS, INC Topic: NEIAbstract DUB Biologics is developing a therapeutic for the prevention and treatment of corneal scarring through knockdown of a novel target that has been shown to be central to the fibrotic response leading to corneal opacification. Corneal opacification severely impairs the vision of 4.2 million people around the world, 5.1% of the total blind population. Monocular scarring is far more common, af ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Neuro-exergaming for the Prevention and Remediation of Decline due to Parkinson's Disease: Clinical Trial of the Interactive Physical and Cognitive Exercise System (iPACES v3)
SBC: iPACES LLC Topic: NINDSPROJECT SUMMARY/ABSTRACT Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer’s disease with prevalence estimated at 0.3% in the general population and at 1% in individuals over age 60 (Getz and Levin, 2017). In addition to the cardinal motor features associated with this illness, individuals with PD also experience cognitive decline. While estimates ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
DermiSphere™: An Advanced Dermal Regeneration Scaffold for Reconstructive Surgery, CRP
SBC: FESARIUSTHERAPEUTICS INC Topic: NIAMSPROJECT SUMMARY/ABSTRACT Due to the inability of the dermis to regenerate on its own, large full thickness skin loss cannot be restored naturally. The current gold standard treatment involves autologous tissue transfer in which the patient serves as their own donor, which may be challenging due to limited availability of full thickness skin donor sites and donor- site morbidity. Dermal Replacement ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients
SBC: Synthis Therapeutics, Inc. Topic: NHLBISynthis Project Summary/Abstract Phase I NHLBIIPF is a chronic, irreversible fibrotic lung disease driven by repeated injury, resulting in progressive stiffening and ultimately, loss of lung function. With 130,000 IPF patients annually and a 5 year mortality rate of 80%, there is significant need for new therapies. To date, conventional therapies have not halted disease progression. Recently 2 new ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Knowledge Engine- A computational approach to combatting dermatological health disparities in underserved communities
SBC: TIFFANY ST BERNARD Topic: 102Abstract - Hair products marketed towards Black women contain a disproportionate amount of toxic or allergenic ingredients, and research suggests that chemical exposure from these products may contribute to health disparities in Black women. Illustrating this, a study of 18 mainstream products commonly used by Black women found that 100% of products contained artificial fragrances known to cause m ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health